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DBackground: Isolated mechanical tricuspid valve replacement (mTVR) is uncommon, early mortality is
reported to be high, and little is known regarding the long-term outcome. We sought to evaluate the
long-term outcome of mTVR.
Methods: From 1980 to 2007, isolated mTVR was performed in 64 patients (33 men) at our institution;
the median age was 45.5 years (6-71 years). There were 2192 tricuspid valve (TV) repairs and 137 isolated
bioprosthetic TV replacements during the same time interval. Valve dysfunction was caused by congenital
TV abnormality in 45 patients (70%), carcinoid heart disease in 13 (20%), traumatic TV regurgitation in
3 (5%), and other reason in 3 (5%). Twenty-three patients (36%) had at least 1 previous cardiac procedure
(TV repair in 8 and bioprosthetic TV replacement in 7).
Results: Mechanical prostheses used included Starr-Edwards (before 1993) in 36 patients (56%) and bileaflet
prostheses in 28 (44%). Concomitant procedures included atrial septal defect closure in 28 (44%), arrhythmia
surgery in 11 (17%), and pulmonary valvectomy for carcinoid disease in 10 patients (16%). Early mortality
occurred in 5 patients (7.8%). Early morbidity included a permanent pacemaker in 9 (14%) and reexploration
for bleeding in 2 patients (3%). Mean follow-up was 6 years (maximum 22.4 years). Five- and 10-year survival
was 65% and 58%, respectively. There was no valve-related mortality. Late morbidity included valve
thrombosis in 5 patients (8%); 3 were managed nonoperatively and 2 underwent TV rereplacement.
Conclusions: Isolated mTVR still leads to increased early mortality. A mechanical valve can be considered
in select situations when anticoagulation is necessary and in the presence of good right ventricular function.
(J Thorac Cardiovasc Surg 2014;148:603-8)Tricuspid valve replacement (TVR) is rarely performed
compared with tricuspid valve (TV) repair. TV repair is
usually the procedure of choice, and, when not possible,
the decision has to be made on which type of prosthetic
valve to use. When TVR is performed, it is usually as a
combined procedure with other valve replacements.1
TVR is associated with high early mortality2 and little is
known regarding long-term outcomes.PATIENTS AND METHODS
The current study was approved by the Mayo Foundation Institutional
Review Board. We retrospectively reviewed 64 patients who underwent
isolated mechanical TVR (mTVR) at the Mayo Clinic, Rochester,
Minnesota, between 1980 and 2007. During this period, there were 2192
TV repairs and 137 isolated bioprosthetic TVRs. TV repair was preferred
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The Journal of Thoracic and CaAmong the 64 patients who underwent mTVR, there were 33 men
(52%), ranging in age from 6 to 71 years (mean age, 43.2  15 years).
Congestive heart failure was the presenting symptom in 27 patients
(42.2%). Moderate-severe right ventricular dysfunction was demonstrated
on preoperative echocardiography in 20 patients (31%).
TVR was performed for isolated severe regurgitation in 53 patients
(83%); severe TV stenosis was the main indication for TVR in 3 patients
(4.7%). Severe TV regurgitation caused by Ebstein malformation of the
TV was found in 45 patients (70%), carcinoid heart disease in
13 (20%), and a double outlet right ventricle in 1 patient (1.6%).
Two patients (3%) had distortion of the TV by the prosthetic patch that
was used for a previous ventricular septal defect closure, and 1 patient
(1.6%) had moderate-severe TV regurgitation as a result of radiation-
induced heart disease. One patient had lupus anticoagulant syndrome
causing TV disease and requiring life-long anticoagulation.
Eight patients (12%) had previous TV repair; 5 patients (8%) had 1
previous TVR and 2 patients (3%) had 2 previous TVRs. Mechanical
prostheses used were Starr-Edwards (Edwards Lifesciences, Irvine, Calif)
in 36 patients (56%; all before 1993), St Jude Medical (St Jude Medical,
Inc, St Paul, Minn) bileaflet in 15 (24%), and CarboMedics
(Sulzer Carbomedics, Inc, Austin, Tex (division of Sulzer Medica))
bileaflet in 13 (20%) patients.
Concomitant procedures with TVR (Table 1) were closure of an atrial
septal defect in 28 patients (44%), arrhythmia surgery in 11 (17%),
pulmonary valvectomy for carcinoid heart valve disease in 10 (16%),
pulmonary valvotomy in 1 (1.6%), repair of a ruptured sinus of Valsalva
aneurysm in 1 (1.6%), pericardiectomy in 1 (1.6%), and coronary artery
bypass grafting in 1 (1.6%). Standardmedian sternotomywas the approach
in 63 patients (98%); 1 TVR (1.6%) was performed through a right thora-
cotomy. TVR was performed without aortic crossclamp in 7 patients
(11%). Warfarin was used for postoperative anticoagulation in all patients.rdiovascular Surgery c Volume 148, Number 2 603
Abbreviations and Acronyms
INR ¼ international normalized ratio
mTVR ¼ mechanical tricuspid valve replacement
TV ¼ tricuspid valve
TVR ¼ tricuspid valve replacement
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DStatistical Analysis
Descriptive statistics for categorical variables are reported as the
frequency and percentage; continuous variables are reported as the mean
(standard deviation) or median (range) as appropriate. The differences
before and after TVR were analyzed. Survival analysis and analysis of
freedom from reoperation and thrombosis were performed by the
Kaplan-Meier method. SAS 9.13 (SAS Institute, Inc, Cary, NC) was the
software used for statistical analysis.TABLE 1. Concomitant procedures
Procedure
Number
of patients Percentage (%)
Atrial septal defect closure 28 44
Arrhythmias surgery 11 17
Pulmonary valvectomy 10 16
Pulmonary valvotomy 1 1.6
Repair of ruptured sinus of
Valsalva aneurysm
1 1.6
Pericardiectomy 1 1.6
Coronary artery bypass graft 1 1.6RESULTS
There were 5 early deaths (7.8%). There have been no
early deaths since 1994. Survival at 5 and 10 years was
65% and 58%, respectively (Figure 1, A). Overall survival
was significantly lower compared with the white population
in the state of Minnesota (Figure 1, B). Overall survival for
patients with Ebstein malformation was 81.8%, 76.4%, and
71.9% at 1, 5, and 10 years, respectively (Figure 1, C);
survival for patients with carcinoid heart disease was
41.7% and 20.8% at 1 and 5 years, respectively
(Figure 1, D). Survival was higher at all times in the
CarboMedics and St Jude Medical groups compared with
the Starr-Edwards group (88.9% and 71.4% vs 69%,
respectively) (Figure 2). There were 22 late deaths;
18 occurred before 1999; the cause was unknown in
10 patients, 6 patients died of progression of their carcinoid
disease with hepatic metastases; 5 patients died of heart
failure, and 1 patient died of complications from embolic
stroke caused by bacterial endocarditis on his native aortic
and mitral valves. No valve-related mortality was reported.
Early reoperation included reexploration for bleeding in
2 patients (3%). Two patients had early anticoagulation-
related bleeding; 1 patient required reexploration and the
other required percutaneous echo-guided pericardiocente-
sis. Permanent epicardial pacemaker implantation was
required in 9 patients (14%). The indications for pacemaker
implantation were complete heart block in 4 patients,
brady-tachy syndrome in 2, sinus node dysfunction in 1;
the other 2 patients underwent a concomitant cryomaze
procedure at the time of TVR and experienced high-grade
atrioventricular block postoperatively.
Mean follow-up was 6 years (maximum, 22.4 years).
Freedom from late reoperation at 1, 5, and 10 years was
95.1%, 92.1%, and 92.1%, respectively (Figure 3).
Freedom from reoperation was higher in the CarboMedics
and St Jude Medical groups at 5 and 10 years compared
with the Starr-Edwards group (100%, and 90.9% vs
90.4%, respectively). Late reoperation occurred in 2604 The Journal of Thoracic and Cardiovascular Surgpatients (3%) who required TV rereplacements for
thrombosed prostheses.
There were no episodes of structural valve deterioration
or prosthetic valve endocarditis reported during the
follow-up period. Freedom from valve-related thrombosis
at 1, 5, and 10 years was 97.3%, 87%, and 87%,
respectively (Figure 4, A). Freedom from valve-related
thrombosis was higher in the St Jude Medical and
CarboMedics groups than the Starr-Edwards group at
1 year (100% vs 95.2%, respectively), but at 5 years, it
was higher in the St JudeMedical and Starr-Edwards groups
compared with the CarboMedics group (100%, 95.2% vs
37.5%, respectively) (Figure 4, B). Valve thrombosis
occurred in 5 patients (8%); 4 of them had a therapeutic
international normalized ratio (INR), at least moderate right
ventricular dysfunction, and a dilated right ventricle. Valve
thrombosis occurred despite adequate anticoagulation and a
therapeutic INR at the time of identification. Two patients
responded to thrombolytic therapy only and 2 required
TV rereplacement. For the last patient, anticoagulation
had to be held because of recent spine surgery and valve
thrombosis responded to thrombolytic therapy after a failed
attempt at percutaneous catheter balloon thrombectomy
(Figure 5, A and B); the patient did not require reoperation.
No anticoagulation-related bleeding occurred during late
follow-up.DISCUSSION
TV repair is the technique preferred by many surgeons
for treating moderate to severe TV regurgitation. TVR,
despite becoming less attractive option in recent years,3,4
still has a role in those patients who are not suitable for
repair. A previous study from our institution5 indicated
that adverse outcomes with TVR are related to the
preoperative status; however, a better outcome may be
achieved if the patient undergoes surgery before the onset
of advanced right heart failure. From 1980 to 2007, we
have performed 2192 tricuspid repairs and 201 TVRs,
which includes the cohort of 64 patients in this study who
underwent isolated mTVR.
The prosthesis of choice for TVR is still a matter of
debate,6 and the concern about replacing the TV with aery c August 2014
FIGURE 1. Survival curves: A, overall survival; B, survival of those who underwent isolated TVR compared with the white population of Minnesota;
C, overall survival of patients with Ebstein anomaly; D, overall survival of those with carcinoid heart disease.
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Dmechanical prosthesis relates to the increased risk of valve
thrombosis as well as valve dysfunction related to pannus
formation as seen in previous studies.7 Valve selection
should be based on discussion with the patient, paying
special attention to the patient’s lifestyle, the need for
life-long warfarin therapy, and right ventricular function.
In the current era, percutaneous valve technology has
increased the likelihood of tissue TVR use, recognizingFIGURE 2. Overall survival according to the type of the prosthesis.
The Journal of Thoracic and Capercutaneous replacement as a management option in those
with degeneration.
The question about the type of the prosthesis in the TV
position was asked by Van Nooten and colleagues8 in their
series of 146 TVRs, which included 69 bioprostheses and
77 mechanical prostheses. Their hospital mortality wasFIGURE 3. Freedom from reoperation at 1, 5, and 10 years was 95.1%,
92.1%, and 92.1%, respectively.
rdiovascular Surgery c Volume 148, Number 2 605
FIGURE 4. Freedom from prosthetic mechanical thrombosis: A, overall; and B, based on the type of prosthesis.
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D16.1%. The investigators concluded that the outcome of
TVR is influenced by preoperative and perioperative
variables such as preoperative functional class, hepato-
megaly, ascites, icterus, and increased cardiothoracic
ratio. They indicated their preference for a large-size
bioprosthesis in view of its initial good durability and
low-risk of valve-related events. However, in those with
good life expectancy, an acceptable alternative is a bileaflet
mechanical prosthesis.
Historically, there has been increased mortality with
TVR compared with other types of valve replacement
surgery. The early mortality in our patients was 9.4%,
which was mainly in the early years of the series
(1980-1994), compared with early mortality of 0% for theFIGURE 5. A and B, Cardiac catheterization images showing the technique o
mechanical tricuspid valve (*). This procedure was performed in a patient
perioperatively, which resulted in thrombosis of the tricuspid valve prosthesis
tricuspid valve (*); B, white arrowhead indicates balloon thrombectomy.
606 The Journal of Thoracic and Cardiovascular Surglatter years (1995-2007). This compares favorably with
other series reported.
Mangoni and colleagues9 reported the outcome of
isolated TVR in 15 consecutive patients, 20% of whom
died within 30 days after surgery and 40% died within
3 months. The study by Filsoufi and colleagues10 reported
on 81 patients (mean age, 61 years), including 25 patients
with isolated TVR; the early mortality in this series
was 22% and 47 patients had undergone TVR with a
mechanical prostheses. The investigators identified the
following as risk factors for mortality: urgency of the
operation, age more than 50 years, functional tricuspid
regurgitation, and pulmonary hypertension. In the series
reported by Tokunaga and colleagues,11 there were 31 casesf percutaneous balloon valvuloplasty with thrombectomy for a thrombosed
who underwent spine surgery and his anticoagulation had to be held
. A, White arrow indicates the catheter extending across the mechanical
ery c August 2014
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Dof isolated TVR including only 4 patients who had mechan-
ical prostheses; the hospital mortality was 6.5%.
The largest series was reported by Ratnatunga and
colleagues.12 They reported on their experience from the
United Kingdom Heart Valve Registry comparing midterm
outcomes between mechanical and biological prostheses in
the TV position. A total of 425 patients underwent TVR;
225 patients (52.9%) received biological prostheses and
200 received mechanical prostheses. The early mortality
in this study was 17.3%; 1-, 5-, and 10-year survival rates
were 72.2%, 59.9%, and 42.9%, respectively. Predictors
of overall survival included the year of the operation, age,
and the number of valves implanted. Early mortality,
although not statistically significant, was higher with the
biological valves compared with the mechanical valves
(18.8% vs 15.6%). Survival rates at 1, 5, and 10 years
were 70.5%, 61.5%, and 47.7% for biological valves and
74.0%, 57.9%, and 33.9% for mechanical valves. In the
study reported by Chang and colleagues,13 the long-term
outcomes of biological and mechanical prostheses were
similar in 138 TVRs (35 biological, 103 mechanical)
performed in 125 patients. Early mortality in that study
was 17.6% and late mortality was 10.4%. The surgical
mortality in that study for biological valves was higher
than for mechanical valves, although this was not
significant. The investigators identified 11 episodes of
thromboembolism in the mechanical group with freedom
from thromboembolism at 5 and 10 years of 90.2  0.6%
and 87.8  0.7%, respectively.
Valve-related thrombosis at 1, 5, and 10 years in this study
was 97.3%, 87%, and 87%, respectively, and it was signif-
icantly higher for the Starr-Edwards and St JudeMedical bi-
leaflet prosthesis. In our 64 cases of mTVR, there were only
5 cases of valve thrombosis more than a year after valve
replacement. Three of these patients hadmoderate or greater
right ventricular systolic dysfunction. All patients reported
therapeutic anticoagulation, and levels were in the appro-
priate range at the time of TVR thrombosis identification.
The risk of mTVR thrombosis was reported to be high in
the early literature, varying between 4% and 20%.14 This
seems to be related to a reduced flow rate and lower
pressure on the right side of the heart.15 The risk of TVR
thrombosis seems to increase in the presence of right
ventricular dysfunction, even in the presence of adequate an-
ticoagulation, as was found in 3 of our patients in this series.
Anticoagulation regimens have also changed over time,16 and
in the current era, anticoagulant and antiplatelet agents are
recommended for all patients with mechanical prostheses.17
We have noticed a lower thrombosis rate with the
Starr-Edwards prosthesis and 1 explanation is the presence
of a larger washing jet in this valve compared with other
mechanical prostheses. That may be of value in the tricuspid
position where the risk of mechanical thrombosis is higher
compared with left-sided prostheses. The differenceThe Journal of Thoracic and Cabetween CarboMedics and St Jude Medical valves is not
clear. However, the same observation has been reported
before in the aortic position by Kandemir and colleagues.18
The investigators reviewed the long-term results between St
Jude Medical and CarboMedics mechanical heart valves in
the aortic position in 174 patients. The freedom from
thromboembolism was 87.7% for the St Jude Medical
group versus 83% for the CarboMedics group. This was
not statistically significant and the investigators attributed
the difference to patient-specific characteristics and the
method of anticoagulation. Others have noticed a higher
thrombosis rate for CarboMedics valves in the mitral
position as well.19 Rosengart and colleagues19 evaluated
245 consecutive patients who underwent mechanical valve
replacement. There were 5 thrombosed valves in the
CarboMedics group and none in the St Jude Medical group
(P ¼ .04), and all thrombosed valves were in the mitral
position. The investigators explained that some of the
design features of the CarboMedics valve could enhance
thromboembolic potentials; for example, the biocompatible
sewing ring may encourage pannus formation and a valve
opening profile may affect washout of stagnant flow areas
where thrombus might form.
The use of bileaflet, especially St Jude Medical,
prostheses has been associated with a low rate of thrombosis
(freedom from thromboembolism was 92.6%  6.9%).20
The high rate of mechanical valve thrombosis reported
previously was mainly in the early era of caged ball and
tilting disc prostheses,21 and before aspirin therapy
was routinely recommended for patients with a mechanical
valve on warfarin.
Thrombosed mechanical TVRs can occasionally be
salvaged by thrombolysis, however reoperation may be
required in the presence of a large clot burden, marked
prosthetic dysfunction, or contraindications to lytic therapy.
Five thrombosed mechanical prostheses were identified
in our series. Three patients underwent successful
thrombolytic therapy, including 1 patient after failed
percutaneous thrombectomy; reoperation was performed
in the other 2. The optimal way to manage thrombosed
TVR remains controversial.
Thrombolytic therapy was first reported in 1971 by
Luluaga and colleagues22 who used streptokinase to treat
thrombosed Starr-Edwards TV prostheses. This approach
has been associated with lower morbidity and mortality
and is usually the recommended first step for thrombosed
right-sided prostheses.23 Repeated thrombolysis was
described in a 49-year-old woman with Ebstein anomaly
who was treated with mTVR. She had 7 episodes of
prosthetic thrombosis and all were managed with throm-
bolysis; she continued to be symptom free for 5 years
after her last thrombotic event.24 In addition, in our study,
no patient had any valve-related mortality or structural
valve failure that required reoperation.rdiovascular Surgery c Volume 148, Number 2 607
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DEvaluation of right ventricular function is critical
when TVR is considered. In the meantime, its complex
geometry makes this evaluation a challenge. In our study,
echocardiography was the only available method of
evaluation, especially in the early era; however, magnetic
resonance imaging is now used more frequently to evaluate
right ventricular function preoperatively. The following
are some of the proposed markers of right ventricular
dysfunction: right ventricular ejection fraction, the
presence of right ventricular dilatation, tricuspid annular
velocity or excursion, right ventricular index of myocardial
performance, TV regurgitation, and pressure-volume or
pressure-area loops.25
In conclusion, TVR with a mechanical prosthesis still
has its place and indications. The long-term outcome is satis-
factory, with good durability and excellent freedom from re-
operation. Based on our experience, we recommend
considering use of a mechanical valve in the tricuspid
position in patients who require warfarin anticoagulation,
thosewith good right ventricular function, and less thanmod-
erate right ventricular dilatation. Our preference is a low-
profile bileaflet mechanical prosthesis. To achieve a good
surgical outcome, patients may need to be referred earlier
to surgery before the development of frank end-stage right
ventricular dysfunction with associated right heart failure.References
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